Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Manolete shares slump on settlement slowdown and delayed payments

(Sharecast News) - Shares in insolvency litigation financer Manolete Partners headed south early on Tuesday after it revealed a slowdown in large case settlements and delayed payments from a small number of large debtors.

Manolete said it had onboarded 114 new cases in the five months ended 31 August, generating unaudited unrealised revenue of £4.2m, up from £3.1m across 87 cases in the same period last year. It also confirmed settlement of one of its truck cartel cases, delivering a £3.2m cash injection largely used to reduce debt.

However, while Manolete said the financial year had begun strongly, it noted a slowdown in large case settlements over the past 12 weeks. Four cases settled above £250,000 during the period, compared with ten in the prior year, contributing to lower average realised revenue per completed case, excluding the cartel settlement.

The London-listed group said activity levels had not been linear across the year, with a number of higher-value completions expected in the coming months and a robust pipeline of potential signings, leaving it confident in its full-year outlook, although it does expect realised revenues to be significantly weighted towards the second half.

Manolete added that a small number of large debtors had recently delayed payments, and combined with lower realised revenue, the company's facility remains drawn to £12.5m.

As of 0855 BST, Manolete Partners shares had slumped 10.43% to 103p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.